Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures

Elmets, Craig A.; Korman, Neil J.; Prater, Elizabeth Farley; Wong, Emily; Rupani, Reena; Kivelevitch, Darío; Armstrong, April W.; Connor, Cody; Cordoro, Kelly M.; Davis, Dawn M.; Elewski, Boni E.; Gelfand, Joel M.; Gordon, Kenneth B.; Gottlieb, Alice B.; Kaplan, Daniel H.; Kavanaugh, Arthur; Kiselica, Matthew; Kroshinsky, Daniela; Lebwohl, Mark; Leonardi, Craig L.; Lichten, Jason; Lim, Henry W.; Mehta, Nehal N.; Paller, Amy S.; Parra, Sylvia L.; Pathy, Arun L.; Siegel, Michael; Stoff, Benjamin K.; Strober, Bruce; Wu, Jashin J.; Hariharan, Vidhya; Menter, Alan

doi:10.1016/j.jaad.2020.07.087

Cited by 185 publications

(233 citation statements)

References 225 publications

(302 reference statements)

Supporting

Mentioning

181

Contrasting

Unclassified

Order By: Relevance

“…Psoriasis, even when involving the face or hands, is not a contraindication to face coverings and hand washing, respectively, and a variety of approaches can be applied to mitigate skin irritation (E-Table VII, available via Mendeley Data, V2, at https://doi.org/ 10.17632/w5m8jf94m8). [106][107][108] Patients with psoriatic disease should receive the seasonal inactivated (eg, killed) influenza vaccine, which is of special importance to individual and public health during the COVID-19 pandemic (Guidance 4.4). Providers may consider temporary discontinuation of methotrexate for 2 weeks after the influenza immunization to…”

Section: Resultsmentioning

confidence: 99%

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

Gelfand

Armstrong

Bell

et al. 2020

Journal of the American Academy of Dermatology

Self Cite

View full text Add to dashboard Cite

Objective To provide guidance about management of psoriatic disease during the COVID-19 pandemic. Study Design A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by non-voting members which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted. Results The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus, 13 with moderate consensus. Limitations The evidence behind many guidance statements is limited in quality. Conclusion These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with SARS-CoV-2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge.

show abstract

Section: Resultsmentioning

confidence: 99%

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

Gelfand

Armstrong

Bell

et al. 2020

Journal of the American Academy of Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Evidence also exists that severe forms of psoriasis may lead to increased alcohol use [46]. In a robust search covering almost 40 years of reports, alcohol, along with other behavioral factors, was found to have an independent association with psoriasis that may influence several comorbidities of the disease as well [47].…”

Section: Role Of Psoriasis In Alcohol Consumptionmentioning

confidence: 99%

“…They further recommended that those with alcohol and concomitant nicotine dependency should be referred to healthcare specialists for further support (the strength of the recommendation was A). Additionally, they described that since the avoidance of alcohol consumption can lead to the improvement of psoriasis, the dermatologist should possibly play a supportive/helping role in informing the patients of that matter [47].…”

Section: Patient Managementmentioning

confidence: 99%

Alcohol in Psoriasis—From Bench to Bedside

Szentkereszty-Kovács

Gáspár

Szegedi

et al. 2021

IJMS

View full text Add to dashboard Cite

Alcohol affects the symptoms, compliance and comorbidities as well as the safety and efficacy of treatments in psoriatic patients. In this review, we aim to summarize and link clinical observations with a molecular background, such as signaling pathways at the cellular level and genetic variations, and to provide an overview of how this knowledge could influence our treatment selection and patient management.

show abstract

“…Among the most commonly used topical therapies for psoriasis are topical corticosteroids (TCS), vitamin D analogues, and the retinoid tazarotene (TAZ) [7]. These treatments are available in a variety of formulations and address the pathophysiology of psoriasis through anti-inflammatory, antiproliferative, immunosuppressive, and vasoconstrictive mechanisms of action [5,[8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits

Lebwohl

Tanghetti

Gold

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Psoriasis is a lifelong disease associated with cycles of remission and relapse. Topical treatments are the front line of psoriasis therapy for most patients and have antiproliferative, antiinflammatory, and immunosuppressive mechanisms of action. Novel fixed-dose combinations of topical therapeutic agents are becoming increasingly available, leveraging multiple mechanisms of action to improve safety and efficacy with formulations that are easier to use and may allow for the use of lower doses of active ingredients. A fixed-combination lotion containing the potent-to-superpotent corticosteroid halobetasol propionate (HP) and the retinoid tazarotene (HP 0.01%/TAZ 0.045%) was recently developed using polymeric emulsion technology. This new formulation technology allows for more uniform and efficient delivery of the active ingredients at lower doses than conventional monotherapy formulations of either ingredient while providing enhanced hydration and moisturization. This review provides an up-to-date overview of the therapeutic mechanisms of action of HP and TAZ, the rationale behind the development of HP 0.01%/ TAZ 0.045% lotion, and clinical trials data on the efficacy, safety and tolerability, and maintenance of therapeutic effect with HP 0.01%/ TAZ 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis.

show abstract

Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures

Cited by 185 publications

References 225 publications

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

Alcohol in Psoriasis—From Bench to Bedside

Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits

Contact Info

Product

Resources

About